Molecular characterization of musculoskeletal tumors by proton MR spectroscopy

Seminars in Musculoskeletal Radiology

Volumn 11, Issue 3, 2007, Pages 240-245

  Fayad, Laura M ^a   Barker, Peter B ^a   Bluemke, David A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; MR spectroscopy; Neoplasm; Soft tissue

Indexed keywords

CHOLINE;

BONE TUMOR; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE ENHANCEMENT; IMAGING SYSTEM; METABOLITE; MUSCLE TUMOR; NON INVASIVE MEASUREMENT; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL NOISE RATIO;

BONE NEOPLASMS; CHOLINE; CREATINE; HUMANS; LIPID METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS; SOFT TISSUE NEOPLASMS;

EID: 39449136758     PISSN: 10897860     EISSN: 1098898X     Source Type: Journal    
DOI: 10.1055/s-2008-1038313     Document Type: Conference Paper

References (30)

1. Biondetti PR, Ehman RL. Soft-tissue sarcomas: Use of textural patterns in skeletal muscle as a diagnostic feature in postoperative MR imaging. Radiology 1992;183:845-848
2. Vanel D, Lacombe MJ, Coanet D, Kalifa C, Spielmann M, Genin J. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology 1987;164:243-245
3. Reuther G, Mutscheler W. Detection of local recurrent disease in musculoskeletal tumors: magnetic resonance imaging versus computed tomography. Skeletal Radiol 1990;19:85-89
4. De Schepper AM, De Beuckeleer L, Vandevenne J, Somville J. Magnetic resonance imaging of soft tissue tumors. Eur Radiol 2000;10:213-222
5. Ilaslan H, Sundaram M. Advances in musculoskeletal tumor imaging. Orthop Clin North Am 2006;37:375-391
6. Crim JR, Seeger LL, Yao L, Chandnani V, Eckardt JJ. Diagnosis of soft-tissue masses with MR imaging: can benign masses be differentiated from malignant ones? Radiology 1992;185:581-586
7. Kransdorf MJ, Murphey MD. Radiologic evaluation of soft-tissue masses: a current perspective. AJR Am J Roentgenol 2000;175:575-587
8. Berquist TH, Ehman RL, King BF, Hodgman CG, Ilstrup DM. Value of MR imaging in differentiating benign from malignant soft-tissue masses: study of 95 lesions. AJR Am J Roentgenol 1990;155:1251-1255
9. May DA, Good RB, Smith DK, Parsons TW. MR imaging of musculoskeletal tumors and tumor mimickers with intravenous gadolinium: experience with 242 patients. Skeletal Radiol 1997;26:2-15
10. Castillo M, Kwock L, Mukherji SK. Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17:1-15
11. Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991;4:47-52
12. Kwock L, Smith JK, Smith JK, et al. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol 2006;7:859-868
13. Oya N, Aoki J, Shinozaki T, Watanabe H, Takagishi K, Endo K. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Radiat Med 2000;18:193-198
14. Fayad LM, Bluemke DA, McCarthy EF, Weber KL, Barker PB, Jacobs MA. Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization. J Magn Reson Imaging 2006;23:23-28
15. Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology 2004;232:599-605
16. Fayad LM, Barker PB, Jacobs MA, et al. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. AJR Am J Roentgenol 2007;188:1513-1520
17. Gonen O, Gruber S, Li BS, Mlynarik V, Moser E. Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0 T: signal-to-noise ratio and resolution comparison. AJNR Am J Neuroradiol 2001;22:1727-1731
18. Futterer JJ, Scheenen TW, Huisman HJ, et al. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 2004;39:671-680
19. Li CW, Kuo YC, Chen CY, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn Reson Med 2005;53:770-776
20. Katz-Brull R, Rofsky NM, Lenkinski RE. Breathhold abdominal and thoracic proton MR spectroscopy at 3T. Magn Reson Med 2003;50:461-467
21. Bolan PJ, Meisamy S, Baker EH, et al. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003;50:1134-1143
22. Baik HM, Su MY, Yu H, et al. Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA 2006;19:96-104
23. Verstraete KL, Lang P. Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur J Radiol 2000;34:229-246
24. Shapeero LG, Vanel D, Verstraete KL, Bloem JL. Dynamic contrast-enhanced MR imaging for soft tissue sarcomas. Semin Musculoskelet Radiol 1999;3:101-114
25. van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol 1998;27:57-71
26. Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 1999;10:277-285
27. Reddick WE, Bhargava R, Taylor JS, Meyer WH, Fletcher BD. Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging 1995;5:689-694
28. Kumar M, Jagannathan NR, Seenu V, Dwivedi SN, Julka PK, Rath GK. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study. J Magn Reson Imaging 2006;24:325-332
29. Madhu B, Waterton JC, Griffiths JR, Ryan AJ, Robinson SP. The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. Neoplasia 2006;8:560-567
30. Alexander A, Murtha A, Abdulkarim B, et al. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med 2006;29:301-311